Fiscal

Teekay Group to Announce Fourth Quarter and Annual 2023 Earnings Results on February 22, 2024

Retrieved on: 
Wednesday, February 14, 2024
TK, Fiscal

HAMILTON, Bermuda, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Teekay Corporation (Teekay) (NYSE:TK) and Teekay Tankers Ltd. (Teekay Tankers) (NYSE:TNK) plan to release their financial results for the fourth quarter and annual 2023 before market open on Thursday, February 22, 2024.

Key Points: 
  • HAMILTON, Bermuda, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Teekay Corporation (Teekay) (NYSE:TK) and Teekay Tankers Ltd. (Teekay Tankers) (NYSE:TNK) plan to release their financial results for the fourth quarter and annual 2023 before market open on Thursday, February 22, 2024.
  • Teekay Tankers plans to host a conference call on Thursday, February 22, 2024 at 11:00 a.m. (ET) to discuss its results for the fourth quarter and annual 2023.
  • All shareholders and interested parties are invited to listen to the live conference call by choosing from the following options:
    By dialing 1(800) 239-9838 or (647) 794-4605 if outside of North America, and quoting conference ID code 2852672.
  • Accompanying Teekay Tankers Fourth Quarter and Fiscal 2023 Earnings Presentation will also be available at www.teekay.com in advance of the conference call start time.

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
AmerisourceBergen, EMA, Injection, Committee, Fiscal, CRL, Outlook, MAA, Ranibizumab, FDA, Calendar, Completion, Bevacizumab, Symantec Endpoint Protection, Chemistry, Therapy, CHMP, European Medicines Agency, AMD, Patient, SPA, Retina, CMC

ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.

Key Points: 
  • ISELIN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced financial results for first quarter fiscal year 2024 and provided a corporate update.
  • Importantly, the first subject was enrolled in NORSE EIGHT in January 2024,” commented Russell Trenary, President and Chief Executive Officer.
  • In January 2024, Outlook Therapeutics announced that it received written agreement on the NORSE EIGHT trial protocol from the FDA under a SPA for NORSE EIGHT.
  • Outlook Therapeutics expects NORSE EIGHT topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024.

SiteOne Landscape Supply Announces Fourth Quarter and Full Year 2023 Earnings

Retrieved on: 
Wednesday, February 14, 2024
Landscape, Other Retail, Retail, Construction & Property, Specialty, Growth, Doug Black, Adjustment, PVC, Fourth, Fiscal

SiteOne Landscape Supply, Inc. (the “Company” or “SiteOne”) (NYSE: SITE) announced earnings for its fourth quarter (“Fourth Quarter 2023”) and full fiscal year ended December 31, 2023 (“Fiscal 2023”).

Key Points: 
  • SiteOne Landscape Supply, Inc. (the “Company” or “SiteOne”) (NYSE: SITE) announced earnings for its fourth quarter (“Fourth Quarter 2023”) and full fiscal year ended December 31, 2023 (“Fiscal 2023”).
  • Gross profit increased 8% to $326.6 million for the Fourth Quarter 2023 compared to $302.6 million for the prior-year period.
  • Net loss for the Fourth Quarter 2023 was $3.4 million, compared to a Net loss of $0.9 million in the prior-year period.
  • Adjusted EBITDA increased 3% to $39.9 million for the Fourth Quarter 2023, compared to $38.9 million for the prior-year period.

Great Elm Group Reports Fiscal 2024 Second Quarter Financial Results

Retrieved on: 
Tuesday, February 13, 2024
Investment, GEG, Growth, Conference, Great Elm, SPV, Fiscal, Cryptocurrency

WALTHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal second quarter ended December 31, 2023.

Key Points: 
  • WALTHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal second quarter ended December 31, 2023.
  • Great Elm launched a credit fund, Great Elm Credit Income Fund, LLC (“GECIF”), during the quarter, focused on income generation and capital preservation through direct lending, syndicated credit and opportunistic credit investing.
  • Great Elm collected incentive fees for the third consecutive quarter from Great Elm Capital Corp. (“GECC”), totaling $0.7 million for the three months ended December 31, 2023.
  • Discussion of Financial Results for the Fiscal Second Quarter Ended December 31, 2023
    GEG reported total revenue of $2.8 million, a 50% increase from $1.9 million in the prior-year three-month period.

Organigram Reports First Quarter Fiscal 2024 Results

Retrieved on: 
Tuesday, February 13, 2024
Retail, Specialty, Other Retail, Thomas Edison, BAT, F1, Multimedia, TSX, THCV, Purchasing, OGI, Adjustment, Risk, Seed, Edible, PDC, WHC, Half-life, Cannabis, Fiscal, Depreciation

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended December 31, 2023 (“Q1 Fiscal 2024”).

Key Points: 
  • Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced its results for the first quarter ended December 31, 2023 (“Q1 Fiscal 2024”).
  • View the full release here: https://www.businesswire.com/news/home/20240213404480/en/
    “We certainly kicked off fiscal 2024 with a bang", said Beena Goldenberg, Chief Executive Officer.
  • Q1 Fiscal 2024 saw the introduction of 22 new SKUs to the market for Organigram.
  • In December 2023, we had a record breaking month in shipped recreational sales, stemming from consistent market share gains throughout Q1 Fiscal 2024."

Philip R. Lane: Euro area international financial flows: analytical insights and measurement challenges

Retrieved on: 
Tuesday, February 13, 2024
Brookings Institution, Quarterly Journal of Economics, Journal of Financial Economics, SSRN, Climate change, Map, IMF Economic Review, Nation, Federal Reserve, Statistics, Adjustment, International economics, BEA, Financial economics, Cambridge University Press, Swings, ESS, Bank, Asian Economic Papers, Buildup, ECI, Data, Director of National Parks, WP, Journal, Spes, Banco de Portugal, International Monetary Fund, Foreign direct investment, Communication, Fiscal, Environment, BIS, ESCB, Sector, BRICS, G-20, Capital, External, Frankfurt, Carbon, Insurance, Central bank, European Central Bank, Quarterly Journal, Speech, Appetite, Research, Reproduction, Exchange, Outline, MNE, Aftermath, Answer, Data management, Geography, FDI, Sound, Banco, COVID-19, Policy, Creditor, Role, ECB, Security (finance)

We document how gas price fluctuations have a heterogeneous pass-through to euro area prices depending on the underlying shock driving them.

Key Points: 
  • We document how gas price fluctuations have a heterogeneous pass-through to euro area prices depending on the underlying shock driving them.
  • Supply shocks, moreover, are found to pass through to all components of euro area inflation – producer prices, wages and core inflation, which has implications for monetary policy.

Reklaim Ltd Unveils Profitable Guidance for Fiscal 2023

Retrieved on: 
Monday, February 12, 2024
OTC, Financial statement, CAD, Fiscal

Fiscal 2023 will mark the first full year of profitability for Reklaim Ltd.

Key Points: 
  • Fiscal 2023 will mark the first full year of profitability for Reklaim Ltd.
    NEW YORK, Feb. 12, 2024 /PRNewswire/ - Reklaim Ltd. (TSXV: MYID) (OTC: MYIDF), the destination where consumers can view, edit, add, and option their data to brands and platforms for direct compensation, is providing guidance that it is expecting to achieve full-year profitability for Fiscal 2023 as well as Q4-2023.
  • This milestone would mark the first time Reklaim has experienced full-year profitability.
  • While audited financials are scheduled for release in early April, Reklaim is confident in maintaining a robust growth trajectory in 2024 and building upon the success and profitability it experienced throughout 2023.
  • The company is strategically positioned to sustain its momentum and further enhance its market presence.

CARIBBEAN UTILITIES COMPANY, LTD. (CUC) ANNOUNCES 2023 YEAR END RESULTS AND STRATEGIC MILESTONES

Retrieved on: 
Saturday, February 10, 2024
Carbon, CUC, Electricity, National Energy Program, Capital expenditure, SAIDI, Electric vehicle, Capital, Life cycle, Temperature, Growth, EV, Life, Construction, Fiscal, Public expenditure, Gold, Integrated Resource Plan, Engineering, Kilowatt-hour, Engineering, procurement, and construction, Renewable energy, Accreditation, Certification, Partnership, Natural gas

GRAND CAYMAN, Cayman Islands, Feb. 9, 2024 /CNW/ - Caribbean Utilities Company, Ltd. ("CUC or "the Company") announced its audited results for the twelve months ended December 31, 2023 ("Fiscal 2023") (all figures are in United States Dollars).

Key Points: 
  • GRAND CAYMAN, Cayman Islands, Feb. 9, 2024 /CNW/ - Caribbean Utilities Company, Ltd. ("CUC or "the Company") announced its audited results for the twelve months ended December 31, 2023 ("Fiscal 2023") (all figures are in United States Dollars).
  • Lifecycle upgrades for 68MW generation are in progress with expected completion of 2 of the units (32 MW) in 2024.
  • In 2023, the Company achieved an average annual outage duration time of 1.7 hours per customer which surpasses the United States average 2022 results.
  • Capital Expenditures for Fiscal 2023 were $97.6 million, an increase of $1.8 million from capital expenditures for Fiscal 2022.

Philip R. Lane: Disinflation in the euro area

Retrieved on: 
Friday, February 9, 2024
Consensus, Momentum, Communication, Relaxation, Forecasting, Acceleration, Pressure, Blog, Policy, Central bank, Speech, Noise, Growth, Risk assessment, Trinity College Dublin, BIS, Consensus decision-making, Reproduction, Disinflation, SPF, HICP, Trinity College, Fiscal, Lecture, Risk, Bangladesh Technical Education Board, Frankfurt, Food, European Central Bank, ECB, Conclusion, Cryptocurrency

Emission reduction measures have been adopted at both country and European Union (EU) levels.

Key Points: 
  • Emission reduction measures have been adopted at both country and European Union (EU) levels.
  • This box assesses the impact on euro area real GDP and inflation of green fiscal discretionary measures as included in the December 2023 Eurosystem staff macroeconomic projections.

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, MRCP, Hepatotoxicity, NT2, Neurological disorder, Narcolepsy, WCR, Fiscal, Wakefulness, Caregiver, Head, Patient, ESS, DSM-IV codes, Medicine, Neuron, OX2R, Disease, Epworth Sleepiness Scale, MWT, Pharmaceutical industry

It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal.

Key Points: 
  • It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal.
  • Stimulating the orexin receptor 2 in NT1 patients targets the underlying pathophysiology of the disease to restore orexin signaling.
  • Based on these results, and in consultation with global health authorities, Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024.
  • Results from the Phase 2b trials have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2024 (Fiscal Year 2023).